dm+d

Unassigned

New Medicines

IgA nephropathy

Information

New molecular entity
Chinook Therapeutics
Chinook Therapeutics

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective inhibitor of the endothelin A receptor
IgAN is characterized by the deposition of IgA-containing immune complexes in glomeruli of the kidney, causin inflammatory response that leads to proteinuria and hematuria. IgAN is the most common primary glomerular disease globally and a leading cause of chronic kidney disease (CKD) [1].
IgA nephropathy
Oral